Review Article

Vitreous Mediators in Retinal Hypoxic Diseases

Roberto dell'Omo,1 Francesco Semeraro,2 Giulio Bamonte,3 Francesco Cifariello,1 Mario R. Romano,1 and Ciro Costagliola1

1 Dipartimento di Scienze per la Salute, Università del Molise, Via Francesco de Sanctis, 86100 Campobasso, Italy
2 Dipartimento di Oftalmologia, Università di Brescia, 25121 Brescia, Italy
3 HagaZiekenhuis, 2545 Den Haag, The Netherlands

Correspondence should be addressed to Ciro Costagliola; ciro.costagliola@unimol.it

Received 8 July 2012; Revised 19 October 2012; Accepted 1 December 2012

Academic Editor: Ahmed M. Abu El-Asrar

Copyright © 2013 Roberto dell'Omo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The causes of retinal hypoxia are many and varied. Under hypoxic conditions, a variety of soluble factors are secreted into the vitreous cavity including growth factors, cytokines, and chemokines. Cytokines, which usually serve as signals between neighboring cells, are involved in essentially every important biological process, including cell proliferation, inflammation, immunity, migration, fibrosis, tissue repair, and angiogenesis. Cytokines and chemokines are multifunctional mediators that can direct the recruitment of leukocytes to sites of inflammation, promote the process, enhance immune responses, and promote stem cell survival, development, and homeostasis. The modern particle-based flow cytometric analysis is more direct, stable and sensitive than the colorimetric readout of the conventional ELISA but, similar to ELISA, is influenced by vitreous hemorrhage, disruption of the blood-retina barrier, and high serum levels of a specific protein. Finding patterns in the expression of inflammatory cytokines specific to a particular disease can substantially contribute to the understanding of its basic mechanism and to the development of a targeted therapy.

1. Introduction

Oxygen supply of the retina is provided by a dual circulation. The photoreceptors and the greater portion of the outer plexiform layer receive nourishment from the choriocapillaris, whereas the inner retinal layers are supplied by the superficial and deep capillary plexuses formed by branches of the central artery of the retina. Inner retinal layers show highest sensitivity to hypoxic challenges [1], whereas outer retinal layers are more resistant to a hypoxic stress [2].

The causes of retinal hypoxia are many and varied. Systemic causes include the cardiovascular effects of chronic obstructive airways disease and the ocular ischemic syndrome associated with arterial obstructive conditions such as carotid artery stenosis [3], hyperviscosity syndromes, anemia, and trauma [4, 5]. Most common causes of local retinal hypoxia include retinal artery and vein occlusion, diabetic retinopathy (DR), retinal detachment, uveitis, and retinopathy of prematurity.

The retinal tissue is capable of inducing protective mechanisms such as glycolysis, angiogenesis, vasodilation, and erythropoiesis under hypoxic-ischemic conditions [6]. These mechanisms deemed of putative importance for limiting the damage are lost within hours of the hypoxic-ischemic insult following which cell death and tissue damage occur [7].

Under hypoxic conditions, a variety of soluble factors are secreted into the vitreous cavity including cytokines, chemokines, and growth factors.

Cytokines, which usually serve as signals between neighboring cells, are involved in essentially every important biological process, including cell proliferation, inflammation, immunity, migration, fibrosis, tissue repair, and angiogenesis [8].

Chemokines are multifunctional mediators that can direct the recruitment of leukocytes to sites of inflammation, enhance immune responses, and promote stem cell survival, development, and homeostasis [9].
Growth factors have been detected from ocular fluid of patients with diabetic retinopathy and other retinal disorders [10]. Finding patterns in the expression of inflammatory mediators specific to a particular disease can substantially contribute to the understanding of the basic mechanism of this disease and consequently to the development of a targeted therapy.

2. Dosage of Vitreous Mediators

Recently, a particle-based flow cytometric analysis method (PFCAM) has been established to overcome some of the intrinsic limitations of the conventional enzyme-linked immunosorbent assay (ELISA) and it has been used to analyze the vitreous inflammatory mediators by multiplex bead in patients with several vitreoretinal disorders [11–14].

The technology utilizes microspheres as the solid support for a conventional immunoassay, affinity assay, or DNA hybridization assay which are subsequently analyzed on a flow cytometer. Overall, the fluorescent readout of the flow cytometric assay is more direct, stable, and sensitive than the colorimetric readout of the ELISA. As the ELISA requires enzyme amplification, it is prone to variability and errors in the amount of amplification.

The sensitivity of the flow cytometric systems can be enhanced further by reducing the number of beads per test. This increases the ratio of cytokine to capture antibody in each test without reducing the potential signal strength of the assay (the number of capture antibodies per bead). PFCAMs are more reproducible than the ELISA which exhibits a significant variation between experiments and between plates within experiments. PFCAMs are also more accurate and reliable because the data are calculated from the mean of dozens of beads, each of which functions as an individual replicate. For many cytokines, the multiplexed and uniplexed PFCAM assays are comparable suggesting that multiplexing does not significantly reduce the overall quality of the assay. In contrast, the conventional ELISA has limited capabilities. Finally, PFCAMs are much cheaper than ELISA when six or more cytokines are measured simultaneously.

Despite these advantages of PFCAM over ELISA, it should be kept in mind that, whatever the test used, there are some conditions which can alter the vitreous concentration of a certain protein, independently from the intraocular secretion of the protein itself.

For example, high serum levels of a specific protein could influence its intravitreal concentration. Similarly, the disruption of the blood-retina barrier produces an increase of proteins in the vitreous fluid. Finally, vitreous hemorrhage, which often occurs in conditions like proliferative diabetic retinopathy and vein occlusion, can produce an influx of serum proteins, such as growth factors, into the vitreous fluid.

3. Oxidative Stress

Oxidative stress, which may occur because of an imbalance between the production and the removal of reactive oxygen species (ROS), is considered to be a critical mediator in injury secondary to ischemic disorders.

Superoxide anion (O$_2^-$) is one of the major ROS. The release of O$_2^-$ in retinal ischemia was proven either directly by electron paramagnetic resonance or indirectly by showing diminished damage after the administration of antioxidant drugs such as EGB 761 extracted from Ginkgo biloba, vitamin E, mannitol, superoxide dismutase, and several other compounds [15–20].

The importance of O$_2^-$ is also indicated by the fact that a manganese superoxide dismutase mimetic and transgenic manganese superoxide dismutase gene inhibited ischemia/reperfusion-induced retinal injury and diabetes-induced oxidative stress [21, 22]. ROS formed during oxidative stress can directly attack polyunsaturated fatty acids and initiate ROS chain reactions that result in lipid peroxidation in cellular membranes and a variety of oxidized products, including aldehydes, which are extremely reactive and can damage biological macromolecules. Injury can occur distal to the initial site of ROS attack because aldehydes are relatively long-lived compared with free radicals [23].

The resultant end products are well-known peroxidation markers of polyunsaturated fatty acids and are capable of inducing apoptosis in neuronal cells [24].

3.1. Nitric Oxide

Nitric oxide is synthesized by the enzyme NO synthase (NOS) from L-arginine. NOS exists in three isoforms: neuronal (nNOS) and endothelial (eNOS) which are constitutively expressed and inducible (iNOS). Enhanced nNOS, eNOS, and iNOS expressions have been reported in the retina in response to hypoxia [25]. Glial cells have been suggested to be the major cell types producer [26] but infiltrating leukocytes may also be an important source of iNOS production.

NO has been described to have neuroprotective and neurotoxic roles [27]. For example, NO produced by the eNOS isoform represents a protective response, since it produces vasodilatation and increased blood flow, maintaining retinal perfusion in hypoxic-ischemic conditions [28, 29].

However, besides these beneficial effects, eNOS is also involved in vascular-endothelial-growth-factor (VEGF-) induced vascular hyperpermeability [30].

NO production from nNOS and iNOS contributes to cytotoxicity resulting in cell death and axonal damage. Other than the generation of free radicals, a number of pathways such as N-methyl-D-aspartate-(NMDA-) mediated intracellular Ca$^{2+}$ influx and CREB-mediated transcription of apoptotic proteins such as Bax, Bad, and Bcl-xI are triggered by NO resulting in neuronal death [31–33].

In retinal ischemia, RGCs death has been reported to be due to the involvement of iNOS as it has been observed that iNOS-positive leukocytes enter the ganglion cell layer and surround the RGCs and cause their degeneration. NO induces the proapoptotic cascade in hypoxic neuronal tissues by increasing phosphorylation of Bcl-2 [31]. Other mechanisms by which NO contributes to cytotoxicity may be peroxynitrite-mediated oxidative damage, DNA damage, and energy failure [34–36].
It has been shown that NO can react with the superoxide anion (O$_2^-$) to form peroxynitrite (ONOO$^-$) [37] which is neurotoxic. NO alone, even at high levels, has been reported as nontoxic to cortical neurons, but becomes neurotoxic after its reaction with O$_2^-$ to form ONOO$^-$ [38]. In vitro studies have shown that the formation of ONOO$^-$ increases the VEGF-induced permeability of retinal microvascular endothelial cells [39] and tissue damage through DNA damage reduced cellular antioxidant defenses and lipid peroxidation [40, 41].

A common target for peroxidation is polyunsaturated fatty acids (PUFAs) present in membrane phospholipids. Lipid peroxidation of retinal membrane PUFAs results in the loss of membrane function and structural integrity [42, 43].

For reasons that remain unclear, retinal endothelial cells seem particularly susceptible to peroxidation-induced injury, whereas pericytes, smooth muscle cells, and perivascular astrocytes are relatively resistant [44–47].

The retina is highly susceptible to lipid peroxidation since 20% of its dry weight is composed of lipids containing a high level of different PUFAs including docosahexaenoic acid (DHA; 22:6ω–3), arachidonic acid (AA; 20:4ω–6), and choline phosphoglyceride. Retinal vessels, in contrast to parenchyma, contain saturated fatty acids like stearic acid as well as unsaturated ones including AA and DHA, but the important DHA precursor, eicosapentaenoic acid (20:5ω–3), is not detected in retinal vessels.

A large body of evidence supports the idea that the increase in oxidative stress in retinal microvasculature is a key factor for the development of diabetic retinopathy [48–50].

A large body of evidence has also demonstrated an increase in reactive oxygen species and NO production in different tissues and cell types during diabetes, or after the exposure to high glucose [50, 51], which have been claimed to contribute to the vascular alterations observed in diabetic retinopathy. In fact, oxidative and nitrosative stress have been associated to the increase of apoptosis in retinal endothelial cells exposed to hyperglycemic conditions [49, 52–55].

It has been demonstrated that elevated glucose per se induces an increase in the levels of ROS in retinal endothelial cells [49].

3.2. Excitotoxicity. Glutamate, the excitatory neurotransmitter in the retina, is released by photoreceptors, bipolar cells, and ganglion cells and mediates the transfer of visual signals from the retina to the brain [56].

Augmented release of glutamate and its accumulation in extracellular spaces in hypoxic-ischemic conditions, leading to the activation of glutamate receptors, has been implicated in hypoxic/ischemic neuronal death [57, 58].

Glutamate exerts its action through ionotropic (aminomethyl-propionic-acid (AMPA) N-methyl-D-aspartate (NMDA), and kainate glutamate receptors) and metabotropic receptors [59, 60]. Glutamate receptor-mediated damage has been reported to occur in glaucoma, central, and branch retinal arterial and retinal vein occlusions resulting in the loss of retinal ganglion cells [61].

Neurotoxic effects of glutamate are reported to occur predominantly through the activation of ionotropic glutamate receptors (GluR). NMDA receptors are highly permeable to Ca$^{2+}$ [62–65], their activation resulting in an increase in the intracellular calcium levels [61, 65–67].

Ca$^{2+}$ overload has been reported to be a central event in neuronal death during ischemia [68, 69].

In fact, abnormal higher concentrations of calcium lead to inappropriate activation of enzymes such as proteases, nucleases, and lipases which are harmful to the cellular constituents and generate free radicals as well as cause mitochondrial failure which results in energy depletion and further free radical production [70].

Depolarization of neuronal membranes due to energy failure results in Ca$^{2+}$ influx through the voltage-dependent Ca$^{2+}$ channels followed by Ca$^{2+}$-dependent glutamate release [71] which further increases the extracellular accumulation of glutamate. Activation of ionotropic glutamate receptors also results in influx of Na$^+$ and Cl$^-$ ions, inducing osmotic swelling. Glutamate acting via NMDA receptors activates nNOS [72] and the production of NO [73].

Glutamate-induced activation of AMPA and NMDA receptors has been shown to enhance the production of tumor necrosis factor (TNF)-α [74–76] and interleukin-1β (IL-1β) [77] significantly.

Cooperation between glutamate receptors and inflammatory cytokines may be one of the mechanisms involved in cell damage.

Glutamate toxicity also results in glutathione depletion and oxidative stress [78]. Glutathione is a major cellular antioxidant which protects the cells against oxidative stress [79–81]. Increase in intracellular ROS in response to glutathione depletion has been reported in several studies [82]. Removal of excess glutamate from the extracellular space by glutamate transporters is crucial to terminate glutamate excitotoxicity. Glutamate transporters are responsible for the removal of glutamate from the extracellular fluid in the retina. It has been suggested that excess glutamate accumulation in the extracellular spaces may result from a failure of the glutamate transporters, such as GLAST, in the vicinity of RGCs [83]. Glutamate transporters have been described as necessary to prevent excitotoxic retinal damage and to synthesize glutathione and their deficiency has been reported to result in RGC degeneration [83].

3.3. Role of Inflammation. Hypoxia-ischemia is known to attract macrophages to hypoxic areas through expression of monocye-chemoattractant-protein-(MCP-) 1. The hypoxia-activated macrophages and microglia, the immune effector cells in the retina, release TNF-α which has been reported as a triggering factor to activate the production of interleukin-(IL)-8, VEGF, and MCP-1 in retinal vascular cells and/or glial cells adjacent to microvessels [84].

Several inflammatory molecules including intercellular-adhesion-molecule-(ICAM-) 1, TNF-α, IL-1, NOS, and COX-2 released by activated inflammatory cells and glial elements play a major role in the degeneration of retinal capillaries [85, 86]. Expression of adhesion molecules, intercellular adhesion molecule-(ICAM-) 1, and vascular-cellular-adhesion-molecule-(VCAM-) 1 on the endothelial
cells facilitating leukocyte adhesion and infiltration into the areas of damage, has been reported to be induced by TNF-α and IL-1 [87–90]. ICAM-1 is important for establishing adhesion of leukocytes before their movement across the endothelium into the tissue [91]. IL-1 and TNF-α may also be involved in transcriptional activation of the iNOS gene [92, 93].

The proliferative diabetic retinopathy (PDR) retinal environment is characterized by the upregulation of iNOS, COX-2, ICAM-1, caspase 1, VEGF, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and increased production of NO, prostaglandin E2, and IL-1β, as well as increased permeability and leukostasis. Localized inflammation is responsible for capillary occlusion and degeneration leading to the ischemia-induced vasculogenesis, which results in DR [94].

Increased leukocyte adhesion (via ICAM1-CD18) to retinal vascular endothelium with resulting endothelial damage, breakdown of the blood retina barrier, capillary nonperfusion, and ischemia contribute to neovascularization. Inhibition of integrin α-4, which forms a part of very late antigen 4 (VLA-4) that binds to VCAM-1, decreases TNF-α, VEGF, NF-κB and reduces leukocyte adhesion and vascular leakage [95]. Cytokines produced by inflammatory cells play a central role in the pathogenesis of PDR by promoting leukocyte-mediated damage to retinal vasculature [96].

Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, produced by neutrophils, is associated with leukocyte adhesion and vascular leakage in diabetic maculopathy and neovascularization. NADPH oxidase is a mediator of DR possibly by reducing peroxisome proliferator-activated receptor- (PPAR-) γ and activating the NF-κB pathway [97].

In vitro, apocynin and superoxide dismutase prevented suppression of PPAR-γ in bovine retinal endothelial cells treated with high glucose [97]. In this environment, the balance is shifted in favour of matrix metalloproteinases (MMPs) and away from their inhibitors, tissue inhibitor of matrix metalloproteinases (TIMPs). MMP-2 and MMP-9 actively degrade collagen IV, which is a major component of basement membranes, causing the extracellular matrix degradation needed for angiogenesis in DR.

4. Cytokines

4.1. Tumor Necrosis Factor α. Tumor necrosis factor α is an inflammatory mediator of neuronal death after ischemic injury in the brain and retina [98]. TNF-α is a member of the death-inducing ligand (DIL) family; it triggers the extrinsic pathway of apoptosis and acts through its two primary receptors, TNFR1 (p55) and TNFR2 (p75).

TNF-α was identified and isolated because of antiangiogenic activity; when injected into tumors, it causes tumor vessels to regress resulting in tumor necrosis [99].

So, it is quite clear that TNF-α has antiangiogenic effects, but it may also have proangiogenic effects in some situations. Despite its inhibition of endothelial cell proliferation in vitro, sustained release of TNF-α in cornea or injection of 105 units of recombinant TNF-α into the vitreous cavity of rabbits causes cellular infiltration and neovascularization (NV) in the cornea [100, 101], possibly by induced expression of other proangiogenic proteins such as interleukin-8, VEGF, and fibroblast-growth-factor- (FGF-) 2 [102]. In cultured vascular endothelial cells, TNF-α induces expression of VEGF receptor 2 and neuropilin-1 [103]. In mice, subcutaneous implantation of a pellet containing a low dose (0.01–1 ng) of murine recombinant TNF-α stimulated angiogenesis, while implantation of a pellet containing a high dose (1–5 μg) inhibited angiogenesis demonstrating opposite effects depending upon the concentration [104].

This paradox may be explained in part by the ability of TNF-α to activate 2 intracellular signaling pathways in endothelial cells, one leading to apoptosis [105] and one that promotes survival and proliferation through the activation of nuclear factor-kappa B (NF-κB) [106]. In addition, TNF-α recruits inflammatory cells, which stimulate neovascularization (NV) in some situations and inhibit it in others [107, 108].

Finally, the ability of TNF-α to induce expression of proangiogenic molecules can result in different effects depending upon the makeup of the local cell population and its response to TNF-α. Therefore, the effect of TNF-α in various tissues and disease processes is difficult to predict and must be determined by experimentation.

Increased levels of TNF-α have been demonstrated in proliferative retinopathies and in animal models of retinal NV [109–112]. These increased levels of TNF-α may be collaborating with VEGF to stimulate retinal NV. TNF-α may also contribute to the process in other ways. For instance, leukocytes have been shown to play a role in the pathogenesis of ischemic retinopathies and TNF-α is a chemoattractant for leukocytes [111].

TNF-α also causes breakdown of the blood-retinal barrier [112] which may be related to its stimulation of leukostasis, and therefore TNF-α may contribute to the excessive permeability seen in ischemic retinopathies.

In early diabetic retinopathy, there is an increased release of retinal inflammatory mediators including TNF-α 85, IL-1β, ICAM-1, and angiotensin II [113] along with activation of microglial cells [114]. A soluble TNF-α receptor-Fc hybrid, such as etanercept [115], is able to normalize vascular permeability and leukostasis; this suggests that TNF-α contributes to diabetic retinopathy, perhaps by preventing endothelial-cell damage from adhering leukocytes [86].

4.2. IL-1, IL-6, and IL-8. Patients with PDR have increased vitreal levels of IL-1 and TNF-α, which induce ICAM-1 expression [116]. Aqueous humour levels of IL-6 and VEGF correlate with respective levels in the vitreous and their concentrations increase with severity of disease [117]. Early stage DR is associated with elevated levels of serum CD105 (which is thought to be involved in vascular remodelling) and vitreal VEGF which then decrease through the course of disease progression to severe PDR [118]. IL-6 (T-cell activation), IL-8 (neutrophil chemotaxis), MCP-1, and VEGF levels are also significantly higher in the vitreous of patients with PDR [119]. IL-18, which induces macrophage activation via interferon-gamma, is raised in the sera of patients with diabetes mellitus type 2 and background DR [120]. In line
4.3. High Mobility Group Box-1. High-mobility group box-1 (HMGB1) protein was originally described 30 years ago as a nonhistone DNA-binding protein [122], involved in nucleosome stabilization and gene transcription [123]. HMGB1 is expressed in ganglion cells layer, inner nuclear layer, outer nuclear layer, the inner and outer segments of photoreceptors, and in the retinal pigment epithelial cells in normal retina [124, 125].

In addition to advanced glycation end products (AGEs), HMGB1 is another ligand of the receptor for AGEs [126], which can contribute to the accelerated micro- and macrovasculopathy observed in diabetes [127]. However, HMGB1 may play a key role in the protection of retinal injury after ischemia-reperfusion [128] and is also implicated as an important endogenous danger signalling molecule amplifying the activities of immunostimulatory molecules in a synergistic manner [129, 130].

HMGB1 stimulates membrane ruffling and repair of a mechanically wounded endothelial cell monolayer, causes endothelial cell sprouting, and stimulates neovascularization of chicken embryo chorioallantoic membrane via RAGE [131]. The crucial role of HMGB1 has also been demonstrated in diabetic mice for ischemia-induced angiogenesis through a VEGF-dependent mechanism [132].

HMGB1 might play a role in the upregulation of VEGF-A in retinal ganglion cells after exposure to AGEs. It has been demonstrated that blocking HMGB1 with glycyrrhizin successfully inhibits AGE-BSA-induced upregulation of VEGF-A [133].

Therefore, HMGB1 works as a cytokine or a cofactor that amplifies the effect of the AGE-RAGE axis, in an autocrine/paracrine manner, and mediates the secretion of survival factors including VEGF-A for counteracting the oxidative stress.

5. Chemokines

Chemokines are multifunctional mediators that can direct the recruitment of leukocytes to sites of inflammation, promote inflammation, enhance immune responses, and promote stem cell survival, development, and homeostasis.

They are classified by structure into four groups, designated C, CC, CXC, and CX3C depending on the number and spacing of the cysteine residues in the mature protein.

The CXC chemokines are divided into two subgroups depending on the presence or absence of the sequence glutamic acid-leucine-arginine (ELR) that immediately precedes the first cysteine amino acid in the primary structure of these cytokines. The ELR-containing CXC chemokines are angiogenic. Most non-ELR CXC chemokines such as interferon-γ-inducible protein of 10 KDa (CXCL10/IP-10) potently chemoattract activated T lymphocytes and are angiostatic [134].

5.1. Monocyte Chemotactic Protein-1. Abu El-Asrar et al. [135] demonstrated that in the vitreous humor of eyes with proliferative vitreoretinal disorders, the CC MCP-1 and the CXC chemokine IP-10 are detected at high levels not correlating to serum levels, suggesting an increased local production. Furthermore myofibroblasts in PDR and proliferative vitreoretinopathy membranes express MCP-1 and stromal-cell-derived-factor- (SDF-) 1, and vascular endothelial cells in PDR membranes express MCP-1, SDF-1, and the chemokine receptor CXCR3. The same authors found that MCP-1 levels in the vitreous from cases of active PDR are significantly higher than those in inactive PDR cases.

Collectively these findings provide evidence that increased MCP-1 expression contributes to the development of neovascularization and fibrosis in proliferative vitreoretinal disorders.

Furthermore Hong et al. [136] showed that MCP-1 induces VEGF expression in endothelial cells; therefore, a positive regulatory feedback loop between VEGF and MCP-1 expression by vascular endothelial cells in mediating angiogenesis might exist.

5.2. Fractalkine. Fractalkine (FKN), the sole member of the CX3C chemokine family, is named for its fractal geometry. Silverman et al. demonstrated the presence of FKN in normal cultured microvascular endothelial and stromal cells of the iris and retina in vitro [137].

Vitreous sample from patients with PDR revealed higher FKN concentrations compared with the control and immunodepletion of soluble FKN from PDR vitreous samples caused 36.6% less migration of bovine retinal capillary endothelial cells [138].

Therefore, FKN appears to be a potent angiogenic mediator in vitro and in vivo and may play an important role in ocular angiogenic disorders such as PDR.

5.3. Monokine Induced by Interferon-γ. Monokine induced by interferon-γ (Mig) is principally known as a chemoattractant of activated T cells, but also has an angiostatic activity. Wakabayashi et al. [139] have recently documented a significant elevation of vitreous Mig concentration in DR patients compared with control subjects. The authors also found a significant correlation between vitreous concentrations of Mig and VEGF. It is not clear why Mig, an angiostatic factor, is elevated in the vitreous in DR, where angiogenesis is one of the main pathologies. One possibility is that Mig is elevated as a response to the upregulation of angiogenic factors such as VEGF. A second hypothesis is that Mig in DR...
might be related to chemotaxis of leukocytes rather than to angiostatic functions, because leukostasis is considered one of the pathogenic mechanisms of DR [140].

5.4. Stromal Cell-Derived Factor-1. Stromal cell-derived factor-1 (SDF-1/CXCL12) is a member of the CXC chemokine family that was originally isolated from murine bone marrow stromal cells. CXCR4, a 7-transmembrane-spanning G protein-coupled receptor, is one of the two receptors for SDF-1.

Recent studies have shown that SDF-1/CXCR4 interaction plays an important role in endothelial progenitor cells (EPCs) migration differentiation, proliferation, and survival [141–145]. SDF-1 is upregulated in ischaemic tissues, establishing an SDF-1 gradient favouring recruitment of EPCs from peripheral blood to sites of ischaemia, thereby contributing to accelerated neovascularization [141, 142].

In addition, SDF-1 promotes the chemotaxis of bone-marrow-derived CD34+ stem cells and their differentiation into EPCs in ischaemic tissue and tumours [142, 144, 145]. CXCR4 blockade profoundly inhibits VEGF- and SDF-1-induced migration of EPCs and impairs incorporation of EPCs into sites of ischaemia-induced neovascularization [143].

The finding that VEGF-mediated migration of EPCs was also influenced by CXCR4 antibodies points toward a more general involvement of CXCR4 and its downstream signalling in the homing mechanisms of EPCs.

Butler et al. [146] reported increased SDF-1 levels in vitreous from patients with PDR. In a murine model of retinal ischaemia, upregulation of SDF-1 and CXCR4 was detected in ischaemic retinas. A substantial amount of the increase in CXCR4 was caused by influx of CXCR4-expressing bone-marrow-derived cells. Pharmacological blockade of CXCR4 suppressed ischaemia- and VEGF-induced retinal neovascularization.

In a murine model of proliferative retinopathy, Blom et al. [147] demonstrated that intravitreal injection of blocking antibodies to SDF-1 prevented retinal neovascularization, even in the presence of VEGF.

Recently, it has been demonstrated that stromal CXCR4+ CD34+ cells are closely associated with the new vessels within the epiretinal membranes in eyes with PDR [148].

6. Transcriptional Factors

6.1. Hypoxia-Inducible Factor. Hypoxia-inducible-factor-(HIF-) 1 is a transcription factor that plays an essential role in the systemic homeostasis response to hypoxia. HIF-1 controls the expression of most genes involved in adapting to hypoxic conditions. HIF-1 triggers the activation of several genes that result in the production of VEGF and other angiogenic factors [149–153].

Several researchers have shown that diabetic factors result in HIF-1 production and angiogenesis. Treins et al. [154] have shown that insulin growth factor 1 stimulates accumulation of HIF-1 in human retinal pigment epithelial cells.

VEGF expression seems to be regulated through dual interdependent mechanisms. One involves HIF-1 directly and the other indirectly through NF-kappa B-mediated COX-2 expression and prostaglandin E2 production. Acute intensive insulin therapy exacerbates diabetic bloodretinal barrier breakdown through HIF-1 and VEGF [155].

This could explain why intensive control can result in transient worsening of diabetic retinopathy.

Recently, the presence of HIF-1α in the diabetic membranes has been shown [156]. HIF-1 is found more often and more intensely in diabetic preretinal membranes compared with nondiabetic idiopathic epiretinal membranes [157].

6.2. Nuclear Factor (NF)-κB. NF-κB is an ubiquitous inducible transcription factor that is a master regulator of immune responses, cellular proliferation, and apoptosis. NF-κB is activated under hypoxic conditions and in retinal endothelial cells and pericytes exposed to hyperglycaemia in vitro and in vivo.

Frede et al. reported for the first time the role of NF-κB in controlling HIF-1 gene expression in response to inflammatory stimuli [158]. Later on, a binding site has been identified for NF-κB within the HIF-1α promoter [159]. Hypoxia has been shown to result in the activation of NF-κB that subsequently can bind to the HIF-1α promoter. It is evident that both transcription factors might be crucial regulators for IL-6 and IL-8 expression in vitreous of PDR patients. In contrast to that hypothesis some authors [121] could not detect either NF-κB or HIF-1α activity in vitreous samples isolated from patients with PDR. However, this does not exclude locally increased NF-κB or HIF-1α activity, as it has been previously documented [160]. Locally increased NF-κB or HIF-1α activity may be covered for their total transcription factor levels in vitreous extracts. In addition, there might be a periodic regulation of NF-κB or HIF-1α activity in different hypoxic conditions [161, 162]. To date, the role of NF-κB or HIF-1α in the regulation of PDR process is weakly understood.

7. Growth Factors

7.1. Vascular Endothelial Growth Factor (VEGF). The VEGF family forms a part of the platelet-derived growth factor (PDGF) supergene family members which comprise four major and five minor isoforms: VEGF 121, VEGF 165, VEGF 189, and VEGF 206; VEGF 145, VEGF 148, VEGF 162, VEGF 165b (an inhibitory isoform binding to VEGFR-2), and VEGF 183. These isoforms derive from alternative exon splicing of the VEGF-A gene, located on chromosome 6p21.3 [163, 164] and are classified by their amino acids number. These cytokines bind to cell-surface receptors that belong to the family of tyrosine-kinase receptors [165].

VEGF binds to tyrosine-kinase receptors, VEGFR1 (Flt-1) and VEGFR2 (Flk-1), and also to the neuropilins (NP)-1 and 2, which also function as receptors. VEGF signalling is modulated by angiopoietins that bind to Tie-2 receptors [166].

VEGF-A has been studied extensively and plays a critical role in both vasculogenesis and angiogenesis [164, 167, 168].

The function of VEGF-A isoforms can vary during ocular development. It is generally accepted that in adults the
formation of new blood vessels results exclusively from surrounding preexisting vessels by sprouting, a process referred to as angiogenesis whereas vasculogenesis, defined as the recruitment and in situ differentiation of vascular endothelial cells from circulating bone-marrow-derived endothelial precursor cells, is normally thought to occur only in the embryonic phases of vascular development.

In addition to angiogenesis and vasculogenesis, VEGF-A may participate in the maintenance of some vascular systems in the adult, but little is known of the role of VEGF-A in the maintenance of adult ocular vasculature. Different studies have shown that VEGF has a role in endothelial reparation after damage [169, 170].

VEGF is secreted by macrophages, T cells, retinal pigment epithelial (RPE) cells, astrocytes, pericyetes, and smooth muscle cells in response to hypoxic and inflammatory stimuli. VEGF secretion is inducible by hypoxia-ischemia in vitro and in vivo, via hypoxia-inducible-factor (HIF)-1 dependent transcriptional activation [171]. A 3–12-fold increase in VEGF gene expression has been reported in hypoxia [172–174]. VEGF enhances the adhesion of leukocytes to vascular walls and increases ICAM-1 and VCAM-1 expression in the brain and retina [175–177].

In the eye, ischemic retinopathies such as PDR and retinopathy of prematurity are pathologic events which, through retinal capillary obliteration, promotes retinal ischemia.

Several reports suggest that VEGF is the critical proangiogenic cytokine [178, 179] and that a direct correlation clearly exists between intraocular VEGF levels and ischemic ocular neovascularization [180–182].

Increased production of VEGF and enhanced permeability of blood retinal barrier has been reported in the hypoxic retina and inhibition of VEGF production with melatonin reduces blood retinal barrier permeability [183].

VEGF is involved in retinopathy of prematurity, DR, and age-related macular degeneration, the leading causes of irreversible visual loss in developed countries from infants to the elderly [184].

7.2. Connective Tissue Growth Factor (CTGF). Connective tissue growth factor (CTGF) is a 38 kD cysteine rich heparin-binding protein and is involved in stimulation of proliferation, angiogenesis, migration, extracellular matrix production, cell attachment, cell survival, and apoptosis [147].

CTGF has been proposed to play an important role in tubule-interstitial fibrosis as one of the major mediators of TGF-β. It has been shown to be hypoxia-inducible in human breast cancer cells [185].

However, the precise signalling mechanisms of the hypoxia-induced expression of CTGF remain unclear. CTGF is expressed in vascular beds and acts on multiple cell types. It is important for vessel growth during early retinal development and promotes the fibrovascular reaction in murine retinal ischemia after laser injury [186]. CTGF overproduction is proposed to play a major role in pathways that lead to fibrosis [187] in the vitreous of PDR patients.

The vitreous of PDR patients has elevated levels of both CTGF and VEGF and the ratio between CTGF and VEGF levels dictates the degree of fibrosis and angiogenesis. Raised CTGF levels are associated with VEGF and fibrosis, but only VEGF itself is responsible for neovascularization (NV) in PDR. In vitro, CTGF induced production of fibronectin and VEGF expression had no direct effects on vascular endothelial cells. CTGF may promote formation of proliferative membranes in PDR but not its cicatrization. It may be implicated indirectly in modulating VEGF expression but has no effects on retinal NV [188]. Anti-VEGF therapy can temporarily tip the CTGF/VEGF ratio towards a profibrotic environment [189].

7.3. Stem Cell Factor (SCF). Stem cell factor (SCF), or kit ligand, is a peptide growth factor that exists as a membrane-bound protein but may be cleaved by proteases, such as matrix metalloproteinase-9 (MMP-9), to produce a soluble cytokine [190, 191].

SCF is important for the survival and differentiation of hematopoietic stem cells. The receptor for SCF, the protooncogene c-kit, is a tyrosine kinase that is expressed by bone marrow-derived endothelial stem/progenitor cells [192, 193]. SCF ligand binding leads to phosphorylation and activation of the c-kit receptor and its downstream signaling proteins, which have been implicated in cell proliferation, cell adhesion and cell survival as well as chemotaxis [194–196]. Several studies have demonstrated that SCF/c-kit signaling promotes the survival, migration differentiation, and capillary tube formation of endothelial cells and plays an important role in ischemia-induced neovascularization [190, 192, 194, 196–198]. Abu El-Asrar et al. [199] demonstrated that (1) PDR membranes show immunoreactivity for SCF, c-kit, G-CSF, eNOS, and CXCR4 in vascular endothelial cells; (2) stromal cells expressed SCF, c-kit, eNOS, and CXCR4; (3) c-kit+ cells coexpressed the chemokine receptor CXCR4 and eNOS; (4) the number of blood vessels expressing CD34, c-kit, G-CSF, eNOS, and CXCR4 and the number of stromal cells expressing c-kit, SCF, eNOS, and CXCR4 in membranes from patients with active PDR were significantly higher than those in membranes from patients with inactive PDR; and (5) there were significant correlations between the number of blood vessels expressing the panendothelial marker CD34 and the number of blood vessels expressing SCF, G-CSF, eNOS, and CXCR4 and the number of stromal cells expressing SCF. These data support the notion that bone-marrow-derived cells contribute to neovascularization in PDR epiretinal membranes and that SCF/c-kit signaling may play a role in the pathogenesis of PDR.

7.4. Insuline-Like Growth Factor (IGF-1). IGF-1 is produced locally in the human eye by a variety of cells including RPE cells, retinal capillary pericytes, endothelial cells, Muller cells, and ganglion cells. In cultured human RPE cells, IGF-1 is thought to exert its effect by inducing a dose-dependent increase in IGF-1R phosphorylation and in VEGF mRNA levels. IGF-I1 also stimulates VEGF promoter activity in vitro, mainly via HIF-1alpha and secondarily via NF-kB and AP-1 [200]. In a south Indian cohort, a CA 18-repeat genotype in
the promoter of IGF-1 is implicated in susceptibility to PDR and associated with clinical severity [201].

7.5. Fibroblast-Growth-Factor- (FGF-) 2. Fibroblast growth factor (FGF)-2 is quickly released during the wound-healing process, providing an early stimulus for endothelial cell proliferation in the acute phase immediately after injury. FGF-2 appears able to upregulate VEGF production and acts synergistically in stimulating angiogenesis-platelet-derived growth factor, transforming growth factor-3.

7.6. Erythropoietin (Epo). Erythropoietin, a stimulator of red blood cells, is also a promoter of vascular endothelial cell proliferation and angiogenesis [202]. Both Epo and VEGF respond to hypoxia [203] leading to ischemia-induced angiogenesis. Epo and VEGF are both raised in the vitreous of patients with PDR and act independently of each other [204]. Epo levels are higher than that of VEGF and its inhibition suppresses retinal NV both in vivo and in vitro. Suppression of Epo and VEGF leads to a greater inhibition of retinal NV than when either is inhibited alone. In vitro inhibition of Epo leads to attenuation of endothelial cell proliferation in PDR [205]. In murine models of oxygen-induced retinopathy, inhibition of Epo led to inhibition of retinal NV in vivo and inhibition of retinal endothelial cell proliferation in vitro [204]. Even though this evidence may tempt us to target Epo in the development of a retinal antiangiogenic strategy, we must be cognizant of its neuroprotective effects on retinal cells [206].

8. The Renin-Angiotensin (RAS) System

Human retinas have angiotensin receptor (ATR) type-1 and ATR-2. In human models of DR and hypoxia-induced retinal angiogenesis, the RAS is upregulated leading to the production of VEGF, PDGF, and CTGF leading to microvascular complications, angiogenesis, cell proliferation, and fibrosis [207].

The RAS exerts its effects by the generation of a family of bioactive angiotensin peptides among which angiotensin II (ANG II) and the ATR-1 and ATR-2 receptors are most well characterized [207]. Emerging evidence suggests that an ocular RAS is activated in DR and may contribute to progressive alterations to retinal cells such as pericytes, endothelial cells, neurons, and glia. In the kallikrein-kinin system (KKS), bradykinin (BK) and kallidin and their carboxypeptidase metabolites, des-Arg (9) -BK and des-Arg(10)-kallidin, are the effector peptides exerting their actions via BK type 1 (BK-B1) and BK type 2 (BK-B2) receptors. Both RAS and KKS damage the retinal vasculature and glia in DR via production of VEGF and CTGF [207]. The RAS is also implicated in progression of DR via Ang II. Ang II induces VEGF, which leads to the loss of tight junction proteins causing a breach in the integrity of the BRB. Angiostin receptor blockers that block Ang II receptors reduce VEGF production by retinal endothelial cells and promote the recovery of tight junction proteins thus preventing progression of DR in its early stages [208]. Important cross-talk exists between the RAS system, advanced glycation end products (AGEs), and their receptors (RAGE). AGEs act via RAGE to cause diabetic microvascular complications leading to PDR [209]. CCN1/Cyr61 is a member of the cysteine-rich 61/connexin family of genes. It is a downstream effector of AGE in the diabetic retina and may work synergistically with VEGF to cause ocular angiogenesis and PDR in models of oxygen induced retinopathy (OIR) in mice and streptozotocin (STZ-) induced DM in rats. Levels of both CCN1 mRNA and protein are raised in vitreous of STZ rats and PDR patients (non-diabetics) [210]. AGEs-RAGE-induced VEGF expression is thought to lead to neovascularization in PDR. Olmesartan, an angiotensin II type-1 receptor blocker, inhibited angiogenesis by inhibiting AGE-induced NF-kb promoter activity and consequently NFκb-mediated RAGE expression [211]. AGEs also induce injury of retinal pericytes, which are protected by PEDF expression. Thus, a decrease in PEDF expression can amplify the effect of AGEs on RPE integrity leading to PDR [212].

9. Other Mediators

9.1. Periostin. Periostin is a secreted extracellular matrix (ECM) protein that is found in areas of normal fibrogenesis or pathologic fibrosis and that can directly interact with other ECM proteins such as fibronection, tenasin-C, collagens I and V, and heparin. The high degree of structural and sequence homology of periostin with fascin1 and transforming growth factor β-induced suggests that peristin plays a role in cell adhesion and migration [213].

Yoshida et al. [214] showed that the concentration of periostin in the vitreous of patients with PDR is significantly higher than that in the vitreous of patients without PDR and, differently from the concentration of VEGF or bFGF, it is significantly correlated with the presence of fibrovascular membranes (FVMs). The differences in the correlations between periostin and VEGF are probably because VEGF is upregulated in the retina at an earlier stage in response to ischemia before the development of FVMs [215, 216].

9.2. Apelin. Apelin was first identified as an endogenous ligand of the orphan G-protein-coupled receptor, APJ, from bovine stomach extracts in 1998 [217]. Apelin signaling has recently been identified as an important contributor to angiogenesis [218]. It is reported that both apelin messenger RNA and APJ messenger RNA are highly expressed in the vascular system, especially in endothelial cells [219, 220].

In vitro, apelin was found to stimulate the proliferation and migration of retinal endothelial cells and the vascular tube formation [221]. Apelin might contribute to the formation of FVMs during the development of PDR and apelin may not be directly regulated by VEGF. Consequently, apelin signalling could represent a new promising therapeutic target during pathologic neovascularization associated with PDR [222].

9.3. Adiponectin. Adiponectin (APN) is a polypeptide hormone produced exclusively in adipocytes and circulates
at very high levels in the bloodstream. In experimental studies, APN has been shown to exert anti-inflammatory and antiatherosclerotic effects and to inhibit neointimal thickening and vascular smooth muscle cell proliferation in mechanically injured arteries. Plasma APN concentrations are decreased in obesity, insulin resistance, type 2 diabetes, coronary disease, and hypertension [223]. Several studies have indicated that APN possesses anti-inflammatory properties and thus may negatively modulate the process of atherogenesis [224]. The role of APN in the development of microvascular disease (such as diabetic retinopathy and nephropathy) is largely unknown.

In patients with PDR, aqueous humor levels of APN are significantly higher than those recorded in control subjects and tend to diminish after intravitreal bevacizumab [225, 226]. These increased APN levels may represent a local reparative response to endothelial dysfunction.

Circulating APN levels well correlate with blood inflammatory marker levels, being highest in the presence of chronic inflammatory diseases. This effect is mediated by a downregulation of a TNF-α, whose levels are chronically increased in Type 2 diabetes. These remarks underline the relationships with inflammatory background and clearly indicate the role of APN as an endogenous modulator of microvascular function and inflammation.

References

[1] M. Janáky, A. Grósz, E. Tóth, K. Benedek, and G. Benedek, “Hypobaric hypoxia reduces the amplitude of oscillatory potentials in the human ERG,” Documenta Ophthalmologica, vol. 114, no. 1, pp. 45–51, 2007.

[2] D. Tinjust, H. Kergoat, and J. V. Lovasik, “Neuroretinal function during mild systemic hypoxia,” Aviation Space and Environmental Medicine, vol. 73, no. 12, pp. 1189–1194, 2002.

[3] G. C. Brown and L. E. Magargal, “The ocular ischemic syndrome. Clinical, fluorescein angiographic and carotid angiographic features,” International Ophthalmology, vol. 11, no. 4, pp. 239–251, 1988.

[4] O. Purscher, “Angiopathy retinae traumatica: lymphorrhagien desaugengrundes,” Graefes Archive for Clinical and Experimental Ophthalmology, vol. 82, pp. 347–371, 1912.

[5] S. A. Buckley and B. James, “Purscher’s retinopathy,” Postgraduate Medical Journal, vol. 72, no. 749, pp. 409–412, 1996.

[6] K. Kitagawa, M. Matsumoto M, M. Tagaya et al., “Ischemic tolerance phenomenon found in the brain,” Brain Research, vol. 528, no. 1, pp. 21–24, 1990.

[7] K. Prass, A. Scharff, K. Ruscher et al., “Hypoxia-induced stroke tolerance in the mouse is mediated by erythropoietin,” Stroke, vol. 34, no. 8, pp. 1981–1986, 2003.

[8] J. Vlcek and M. Feldmann, “Historical review: cytokines as therapeutics and targets of therapeutics,” Trends in Pharmacological Sciences, vol. 25, no. 4, pp. 201–209, 2004.

[9] S. Stryuf, P. Proost, and J. van Damme, “Regulation of the immune response by the interaction of chemokines and proteases,” Advances in Immunology, vol. 81, pp. 1–44, 2003.

[10] L. P. Aiello, R. L. Avery, P. G. Arrigg et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,” The New England Journal of Medicine, vol. 331, no. 22, pp. 1480–1487, 1994.

[11] D. A. Vignali, “Multiplexed particle-based flow cytometric assays,” Journal of Immunological Methods, vol. 243, no. 1-2, pp. 243–255, 2000.

[12] S. Banerjee, V. Savant, R. A. H. Scott, S. J. Curnow, G. R. Wallace, and P. L. Murray, “Multiplex bead analysis of vitreous humor of patients with vitreoretinal disorders,” Investigative Ophthalmology and Visual Science, vol. 48, no. 5, pp. 2203–2207, 2007.

[13] R. Maier, M. Weger, E. M. Haller-Schober et al., “Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients,” Molecular Vision, vol. 14, pp. 637–643, 2008.

[14] T. Yoshimura, K. H. Sonoda, M. Sugahara et al., “Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases,” PLoS ONE, vol. 4, no. 12, Article ID e8158, 2009.

[15] M. E. Szabo, M. T. Droy-Lefai, M. Doly, C. Carre, and P. Braquet, “Ischemia and reperfusion-induced histologic changes in the rat retina: demonstration of a free radical-mediated mechanism,” Investigative Ophthalmology and Visual Science, vol. 32, no. 5, pp. 1471–1478, 1991.

[16] M. E. Szabo, M. T. Droy-Lefai, and M. Doly, “Direct measurement of free radicals in ischemic/reperfused diabetic rat retina,” Clinical Neurosciences, vol. 4, no. 5, pp. 240–245, 1997.

[17] S. Y. Kim, J. S. Kwak, J. P. Shin, and S. H. Lee, “The protection of the retina from ischemic injury by the free radical scavenger EGB 761 and zinc in the cat retina,” Ophthalmologica, vol. 212, no. 4, pp. 268–274, 1998.

[18] F. Hirose, J. Kiryu, K. Miyamoto et al., “In vivo evaluation of retinal injury after transient ischemia in hypertensive rats,” Hypertension, vol. 43, no. 5, pp. 1098–1102, 2004.

[19] R. A. Kowluru, V. Kowluru, Y. Xiong, and Y. S. Ho, “Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress,” Free Radical Biology and Medicine, vol. 41, no. 8, pp. 1191–1196, 2006.

[20] B. H. Chen, S. Caballero, S. Seo, M. B. Grant, and A. S. Lewin, “Delivery of antioxidant enzyme genes to protect against ischemia/reperfusion-induced injury to retinal microvasculature,” Investigative Ophthalmology and Visual Science, vol. 50, no. 12, pp. 5587–5595, 2009.

[21] A. Dong, I. Shen, M. Krause et al., “Superoxide dismutase 1 protects retinal cells from oxidative damage,” Journal of Cellular Physiology, vol. 208, no. 3, pp. 516–526, 2006.

[22] M. S. Nayak, M. Kita, and M. F. Marmor, “Protection of rabbit retina from ischemic injury by superoxide dismutase and catalase,” Investigative Ophthalmology and Visual Science, vol. 34, no. 6, pp. 2018–2022, 1993.

[23] H. Esterbauer, R. J. Schaur, and H. Zollner, “Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes,” Free Radical Biology and Medicine, vol. 11, no. 1, pp. 81–128, 1991.

[24] G. Poli and R. J. Schaur, “4-Hydroxynonenal in the pathomechanisms of oxidative stress,” IUBMB Life, vol. 50, no. 4-5, pp. 315–321, 2000.

[25] C. Kaur, V. Sivakumar, and W. S. Foulds, “Early response of neurons and glial cells to hypoxia in the retina,” Investigative Ophthalmology and Visual Science, vol. 47, no. 3, pp. 1126–1141, 2006.

[26] K. Kashiwagi, Y. Iizuka, S. Mochizuki et al., “Differences in nitric oxide production: a comparison of retinal ganglion cells and retinal glial cells cultured under hypoxic conditions,” Molecular Brain Research, vol. 112, no. 1-2, pp. 126–134, 2003.
[27] C. Iadecola, "Bright and dark sides of nitric oxide in ischemic brain injury," Trends in Neurosciences, vol. 20, no. 3, pp. 132–139, 1997.

[28] N. Toda and M. Nakanishi-Toda, "Nitric oxide: ocular blood flow, glaucoma, and diabetic retinopathy," Progress in Retinal and Eye Research, vol. 26, no. 3, pp. 205–238, 2007.

[29] J. P. Bolaños and A. Almeida, "Roles of nitric oxide in brain hypoxia ischemia," Biochimica et Biophysica Acta, vol. 1411, no. 2-3, pp. 415–436, 1999.

[30] D. Fukumura, T. Gohongi, A. Kadambi et al., "Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability," Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 5, pp. 2604–2609, 2001.

[31] O. P. Mishra, A. B. Zubrow, and Q. M. Ashraf, "Nitric oxide-mediated activation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) during hypoxia in cerebral cortical nuclei of newborn piglets," Neuroscience, vol. 123, no. 1, pp. 179–186, 2004.

[32] A. B. Zubrow, M. Delivoria-Papadopoulos, Q. M. Ashraf, K. I. Fritz, and O. P. Mishra, "Nitric oxide-mediated Ca2+/-calmodulin-dependent protein kinase IV activity during hypoxia in neuronal nuclei from newborn piglets," Neuroscience Letters, vol. 335, no. 1, pp. 5–8, 2002.

[33] A. B. Zubrow, M. Delivoria-Papadopoulos, Q. M. Ashraf, J. R. Ballesteros, K. I. Fritz, and O. P. Mishra, "Nitric oxide-mediated expression of Bax protein and DNA fragmentation during hypoxia in neuronal nuclei from newborn piglets," Brain Research, vol. 954, no. 1, pp. 60–67, 2002.

[34] T. Nguyen, D. Brunson, C. L. Crespi, B. W. Penman, J. S. Wishnow, and S. R. Tannenbaum, "DNA damage and mutation in human cells exposed to nitric oxide in vitro," Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 7, pp. 3030–3034, 1992.

[35] R. L. Zhang, M. Chopp, H. Chen, and J. H. Garcia, "Temporal profile of ischemic tissue damage, neutrophil response, and vascular plugging following permanent and transient (2H) middle cerebral artery occlusion in the rat," Journal of the Neurological Sciences, vol. 125, no. 1, pp. 3–10, 1994.

[36] W. L. Gross, M. I. Bak, J. S. Ingwall et al., "Nitric oxide inhibits creatine kinase and regulates heart contractile reserves," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 11, pp. 5604–5609, 1996.

[37] J. S. Beckman, T. W. Beckman, J. Chen, P. A. Marshall, and B. A. Freeman, "Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide," Proceedings of the National Academy of Sciences of the United States of America, vol. 87, no. 4, pp. 1620–1624, 1990.

[38] S. A. Lipton, Y. B. Choi, Z. H. Pan et al., "A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds," Nature, vol. 364, no. 6438, pp. 626–632, 1993.

[39] T. Marumo, T. Noll, V. B. Schini-Kerth et al., "Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor," Journal of Vascular Research, vol. 36, no. 6, pp. 510–515, 1999.

[40] M. G. Salgo, E. Bermúdez, G. L. Squadrtilo, and W. A. Pryor, "Peroxynitrite causes DNA damage and oxidation of thiols in rat thymocytes," Archives of Biochemistry and Biophysics, vol. 322, no. 2, pp. 500–505, 1995.

[41] D. Salvemini, Z. Wang, M. Stern, M. G. Currie, and T. P. Misko, "Peroxynitrite decomposition catalysts: therapeutics for peroxynitrite-mediated pathology," Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 5, pp. 2695–2703, 1998.

[42] S. M. Anderson and N. I. Krinsky, "Protective action of carotenoid pigments against photodynamic damage to liposomes," Photochemistry and Photobiology, vol. 18, no. 5, pp. 403–408, 1973.

[43] A. U. Arstila, M. A. Smith, and B. F. Trump, "Microsomal lipid peroxidation: morphological characterization," Science, vol. 175, no. 4021, pp. 530–533, 1972.

[44] T. Kondo, H. Kinouchi, M. Kawase, and T. Yoshimoto, "Differential response in the release of hydrogen peroxide between astroglial cells and endothelial cells following hypoxia/reoxygenation," Neuroscience Letters, vol. 215, no. 2, pp. 103–106, 1996.

[45] N. Auge, M. T. Pieraggi, J. C. Thiers, A. Negre-Salvayre, and R. Salvayre, "Proliferative and cytotoxic effects of mildly oxidized low-density lipoproteins on vascular smooth-muscle cells," Biochemical Journal, vol. 309, no. 3, pp. 1015–1020, 1995.

[46] P. A. D’Amore and E. Sweet, "Effects of hyperoxia on microvascular cells in vitro," In Vito Cellular and Developmental Biology, vol. 23, no. 2, pp. 123–128, 1987.

[47] M. Halks-Miller, M. Henderson, and L. F. Eng, "α-tocopherol decreases lipid peroxidation, neuronal necrosis, and reactive gliosis in reaggregate cultures of fetal rat brain," Journal of Neuropathology and Experimental Neurology, vol. 45, no. 4, pp. 471–484, 1986.

[48] J. M. Carbajal and R. C. Schaeffer, "H2O2 and genistein differentially modulate protein tyrosine phosphorylation, endothelial morphology, and monolayer barrier function," Biochemical and Biophysical Research Communications, vol. 249, no. 2, pp. 461–466, 1998.

[49] Y. Du, C. M. Miller, and T. S. Kern, "Hyperglycemia increases mitochondrial superoxide in retina and retinal cells," Free Radical Biology and Medicine, vol. 35, no. 11, pp. 1491–1499, 2003.

[50] R. A. Kowluru, "Diabetic retinopathy: mitochondrial dysfunction and retinal capillary cell death," Antioxidants and Redox Signaling, vol. 7, no. 11–12, pp. 1581–1587, 2005.

[51] T. Nishikawa and E. Araki, "Impact of mitochondrial ROS and genistein differentially modulate protein tyrosine phosphorylation, endothelial morphology, and monolayer barrier function," Antioxidants and Redox Signaling, vol. 9, no. 3, pp. 343–353, 2007.

[52] R. A. Kowluru, "Effect of advanced glycation end products on accelerated apoptosis of retinal capillary cells under in vitro conditions," Life Sciences, vol. 76, no. 9, pp. 1051–1060, 2005.

[53] P. Grammas and M. Riden, "Retinal endothelial cells are more susceptible to oxidative stress and increased permeability than brain-derived endothelial cells," Microvascular Research, vol. 65, no. 1, pp. 18–23, 2003.

[54] Y. Du, M. A. Smith, C. M. Miller, and T. S. Kern, "Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine," Journal of Neurochemistry, vol. 80, no. 5, pp. 771–779, 2002.

[55] Á. Castilho, C. A. Aveleira, E. C. Leal et al., "Heme oxygenase-1 protects retinal endothelial cells against high glucose- and oxidative/nitrosative stress-induced toxicity," PLoS ONE, vol. 7, no. 8, Article ID e42428, 2012.
[56] S. C. Massey, “Cell types using glutamate as a neurotransmitter in the vertebrate retina,” Progress in Retinal and Eye Research, vol. 9, pp. 399–425, 1990.

[57] H. Benveniste, J. Drejer, A. Schousboe, and N. H. Diemer, “Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis,” Journal of Neurochemistry, vol. 43, no. 5, pp. 1369–1374, 1984.

[58] Y. M. Lu, B. F. Lu, F. Q. Zhao, Y. L. Yan, and X. P. Ho, “Accumulation of glutamate is regulated by calcium and protein kinase C in rat hippocampal slices exposed to ischemic states,” Hippocampus, vol. 3, no. 2, pp. 221–227, 1993.

[59] J. H. Brandstätter, P. Koulen, and H. Wässle, “Diversity of glutamate receptors in the mammalian retina,” Vision Research, vol. 38, no. 10, pp. 1385–1397, 1998.

[60] T. Gründler, K. Kohler, and E. Guenthe, “Alterations in NMDA receptor expression during retinal degeneration in the RCS rat,” Visual Neuroscience, vol. 18, no. 5, pp. 781–787, 2001.

[61] N. J. Sucher, S. A. Lipton, and E. B. Dreyer, “Molecular basis of glutamate toxicity in retinal ganglion cells,” Vision Research, vol. 37, no. 24, pp. 3483–3493, 1997.

[62] A. B. MacDermott, M. L. Mayer, and G. L. Westbrook, “NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurons,” Nature, vol. 321, no. 6069, pp. 519–522, 1986.

[63] M. Hollmann, M. Hartley, and S. Heinemann, “Ca²⁺ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition,” Science, vol. 252, no. 5007, pp. 851–853, 1991.

[64] B. Rörig and R. Grantyn, “Retinal ganglion cells express Ca²⁺-permeable non-NMDA glutamate receptors during the period of histogenetic cell death,” Neuroscience Letters, vol. 153, no. 1, pp. 32–36, 1993.

[65] R. Siliprandi, R. Canella, G. Carmignoto et al., “N-methyl-D-aspartate-induced neurotoxicity in the adult rat retina,” Visual Neuroscience, vol. 6, no. 6, pp. 567–573, 1992.

[66] N. J. Sucher, E. Aizenman, and S. A. Lipton, “N-methyl-D-aspartate antagonists prevent kainate neurotoxicity in rat retinal ganglion cells in vitro,” Journal of Neuroscience, vol. 11, no. 4, pp. 966–971, 1991.

[67] N. J. Sucher, L. A. Wong, and S. A. Lipton, “Redox modulation of NMDA receptor-mediated Ca²⁺ flux in mammalian central neurons,” Neuroreport, vol. 1, no. 1, pp. 29–32, 1990.

[68] P. Nicotera and S. Orrenius, “The role of calcium in apoptosis,” Cell Calcium, vol. 23, no. 2–3, pp. 173–180, 1998.

[69] R. Sattler and M. Tymianski, “Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death,” Molecular Neurobiology, vol. 24, no. 1–3, pp. 107–129, 2001.

[70] L. L. Dugan, S. L. Sensi, L. M. T. Canzoniero et al., “Mitochondrial production of reactive oxygen species in cortical neurons following exposure to N-methyl-D-aspartate,” Journal of Neuroscience, vol. 15, no. 10, pp. 6377–6388, 1995.

[71] K. Katsura, T. Kristian, and B. K. Siesjo, “Energy metabolism, ion homeostasis, and cell damage in the brain,” Biochemical Society Transactions, vol. 22, no. 4, pp. 991–996, 1994.

[72] G. Garthwaite and J. Garthwaite, “AMPA neurotoxicity in rat cerebellar and hippocampal slices: histological evidence for three mechanisms,” European Journal of Neuroscience, vol. 3, no. 8, pp. 715–728, 1991.

[73] J. P. Kiss and E. S. Vizi, “Nitric oxide: a novel link between synaptic and nonsynaptic transmission,” Trends in Neurosciences, vol. 24, no. 4, pp. 211–215, 2001.

[74] A. De, J. M. Krueger, and S. M. Simasko, “Glutamate induces the expression and release of tumor necrosis factor-α in cultured hypothalamic cells,” Brain Research, vol. 1053, no. 1–2, pp. 54–61, 2005.

[75] M. Noda, H. Nakanishi, J. Nabekura, and N. Akaike, “AMPA-kainate subtypes of glutamate receptor in rat cerebral microglia,” Journal of Neuroscience, vol. 20, no. 1, pp. 251–258, 2000.

[76] C. Matute, E. Alberdi, M. Domencq, F. Pérez-Cerdá, A. Pérez-Samartin, and M. V. Sánchez-Gómez, “The link between excitotoxic oligodendroglial death and demyelinating diseases,” Trends in Neurosciences, vol. 24, pp. 224–230, 2001.

[77] P. Hagan, S. Poole, F. Tilders, and F. S. Silverstein, “Intracerebral NMDA injection stimulates production of interleukin-1β in perinatal rat brain,” Journal of Neurochemistry, vol. 67, no. 5, pp. 2215–2218, 1996.

[78] R. R. Ratan, T. H. Murphy, and J. M. Baraban, “Oxidative stress induces apoptosis in embryonic cortical neurons,” Journal of Neurochemistry, vol. 62, no. 1, pp. 376–379, 1994.

[79] A. Meister and M. E. Anderson, “Glutathione,” Annual Review of Biochemistry, vol. 52, pp. 711–760, 1983.

[80] T. Mizui, H. Kinouchi, and P. H. Chan, “Depletion of brain glutathione by buthionine sulfoximine enhances cerebral ischemic injury in rats,” American Journal of Physiology, vol. 262, no. 2, pp. H313–H317, 1992.

[81] P. J. Bobyn, J. L. Franklin, C. M. Wall, J. A. Thornhill, B. H. J. Juurlink, and P. G. Paterson, “The effects of dietary sulfur amino acid deficiency on rat brain glutathione concentration and neural damage in global hemispheric hypoxia—ischemia,” Nutritional Neuroscience, vol. 5, no. 6, pp. 407–416, 2002.

[82] J. T. Coyle and P. Puttfarken, “Oxidative stress, glutamate, and neurodegenerative disorders,” Science, vol. 262, no. 5134, pp. 689–695, 1993.

[83] T. Harada, C. Harada, K. Nakamura et al., “The potential role of glutamate transporters in the pathogenesis of normal tension glaucoma,” Journal of Clinical Investigation, vol. 117, no. 7, pp. 1763–1770, 2007.

[84] S. Yoshida, A. Yoshida, and T. Ishibashi, “Induction of IL-8, MCP-1, and bFGF by TNF-α in retinal glial cells: implications for retinal neovascularization during post-ischemic inflammation,” Graefe’s Archive for Clinical and Experimental Ophthalmology, vol. 242, no. 5, pp. 409–413, 2004.

[85] L. Zheng, B. Gong, D. A. Hatala, and T. S. Kern, “Retinal ischemia and reperfusion causes capillary degeneration: similarities to diabetes,” Investigative Ophthalmology and Visual Science, vol. 48, no. 1, pp. 361–367, 2007.

[86] A. M. Joussen, V. Poulaki, W. Qin et al., “Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo,” American Journal of Pathology, vol. 160, no. 2, pp. 501–509, 2002.

[87] D. Wong and K. Dorovini-Zis, “Upregulation of intercellular adhesion molecule-1 (ICAM-1) expression in primary cultures of human brain microvessel endothelial cells by cytokines and lipopolysaccharide,” Journal of Neuroimmunology, vol. 39, no. 1–2, pp. 11–22, 1992.

[88] D. C. Hess, T. Bhutwala, J. C. Sheppard, W. Zhao, and J. Smith, “ICAM-1 expression on human brain microvascular endothelial cells,” Neuroscience Letters, vol. 168, no. 1–2, pp. 201–204, 1994.
[89] J. F. McHale, O. A. Harari, D. Marshall, and D. O. Haskard, “TNF-α and IL-1 sequentially induce endothelial ICAM-1 and VCAM-1 expression in MRL/lpr lupus-prone mice,” *Journal of Immunology*, vol. 163, no. 7, pp. 3993–4000, 1999.

[90] G. Feuerstein, X. Wang, and F. C. Barone, “Cytokines in brain ischemia—the role of TNF-α,” *Cellular and Molecular Neurobiology*, vol. 18, no. 6, pp. 695–701, 1998.

[91] J. Wang, H. Beechhuizen, and R. van Furfth, “Surface molecules involved in the adherence of recombinant interferon-γ (rIFN-γ)-stimulated human monocytes to vascular endothelial cells,” *Clinical and Experimental Immunology*, vol. 95, no. 2, pp. 263–269, 1994.

[92] M. O. López-Figueroa, H. E. Day, S. Lee, C. Rivier, H. Akil, and S. J. Watson, “Temporal and anatomical distribution of nitric oxide synthase mRNA expression and nitric oxide production during central nervous system inflammation,” *Brain Research*, vol. 852, no. 1, pp. 239–246, 2000.

[93] H. Kadhim, M. Khalifa, P. Deltenre, G. Casimir, and G. Sébire, “Molecular mechanisms of cell death in periventricular leukomalacia,” *Neurology*, vol. 67, no. 2, pp. 293–299, 2006.

[94] T. S. Kern, “Contributions of inflammatory processes to the development of the early stages of diabetic retinopathy,” *Experimental Diabetes Research*, vol. 2007, Article ID 95103, 14 pages, 2007.

[95] E. Iliaki, V. Poulaki, N. Mitsiades, C. S. Mitsiades, J. W. Miller, and E. S. Gragoudas, “Role of α4 integrin (cd49d) in the pathogenesis of diabetic retinopathy,” *Investigative Ophthalmology and Visual Science*, vol. 50, no. 10, pp. 4890–4904, 2009.

[96] A. P. Adonis and A. J. Berman, “Immunological mechanisms in the pathogenesis of diabetic retinopathy,” *Seminars in Immunopathology*, vol. 30, no. 2, pp. 65–84, 2008.

[97] A. Tawfik, T. Sanders, K. Kahook, S. Akeel, A. Elmarakby, and M. Al-Shabrawey, “Suppression of retinal peroxisome proliferator-activated receptor γ in experimental diabetes and oxygen-induced retinopathy: role of NADPH oxidase,” *Investigative Ophthalmology and Visual Science*, vol. 50, no. 2, pp. 878–884, 2009.

[98] G. Tezel and M. B. Wax, “Increased production of tumor necrosis factor-α by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells,” *Journal of Neuroscience*, vol. 20, no. 23, pp. 8693–8700, 2000.

[99] E. A. Carswell, L. J. Old, R. L. Kassel, N. Fiore, and B. Williamon, “An endothotoxin-induced serum factor that causes necrosis of tumors,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 72, no. 9, pp. 3666–3670, 1975.

[100] M. Fräter-Schröder, W. Risau, R. Hallmann, P. Gautschi, and P. Böhlen, “Tumor necrosis factor type α, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 84, no. 15, pp. 5277–5281, 1987.

[101] J. T. Rosenbaum, E. L. J. Howes, R. M. Rubin, and J. R. Samples, “Ocular inflammatory effects of intravitreally injected tumor necrosis factor,” *American Journal of Pathology*, vol. 133, no. 1, pp. 47–53, 1988.

[102] S. Yoshida, M. Ono, T. Shono et al., “Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor α-dependent angiogenesis,” *Molecular and Cellular Biology*, vol. 17, no. 7, pp. 4015–4023, 1997.

[103] E. Giraudo, L. Primo, E. Audero et al., “Tumor necrosis factor-α regulates expression of vascular endothelial growth factor receptor-2 and of its co-receptor neuropilin-1 in human vascular endothelial cells,” *The Journal of Biological Chemistry*, vol. 273, no. 34, pp. 22128–22135, 1998.

[104] L. F. Fajardo, H. H. Kwan, J. Kowalski, S. D. Prionas, and A. C. Allison, “Dual role of tumor necrosis factor-α in angiogenesis,” *American Journal of Pathology*, vol. 140, no. 3, pp. 539–544, 1992.

[105] L. A. Tartaglia, T. M. Ayres, G. H. W. Wong, and D. V. Goeddel, “A novel domain within the 55 kd TNF receptor signals cell death,” *Cell*, vol. 74, no. 5, pp. 845–853, 1993.

[106] H. Y. Song, C. H. Régnier, C. J. Kirschning, D. V. Goeddel, and M. Rothe, “Tumor necrosis factor (TNF)-mediated kinase cascades: bifurcation of nuclear factor-xB and c-jun N-terminal kinase (JNK/SAPK) pathways at TNF receptor-associated factor 2,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 94, no. 18, pp. 9792–9796, 1997.

[107] S. Ishida, T. Usui, K. Yamashiro et al., “VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization,” *Journal of Experimental Medicine*, vol. 198, no. 3, pp. 483–489, 2003.

[108] R. A. Lang and M. J. Bishop, “Macrophages are required for cell death and tissue remodeling in the developing mouse eye,” *Cell*, vol. 74, no. 3, pp. 453–462, 1993.

[109] D. Armstrong, T. Ueda, T. Ueda et al., “Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-α, vascular endothelial growth factor and platelet-derived growth factor,” *Angiogenesis*, vol. 2, no. 1, pp. 93–104, 1998.

[110] G. Camussi, E. Albano, C. Tetta, and F. Bussolino, “The molecular action of tumor necrosis factor-α,” *European Journal of Biochemistry*, vol. 202, no. 1, pp. 3–14, 1991.

[111] S. Majka, P. G. McGuire, and A. Das, “Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization,” *Investigative Ophthalmology and Visual Science*, vol. 43, no. 1, pp. 260–266, 2002.

[112] N. L. Derevjaniak, S. A. Vinores, W. H. Xiao et al., “Quantitative assessment of the integrity of the blood-retinal barrier in mice,” *Investigative Ophthalmology and Visual Science*, vol. 43, no. 7, pp. 2462–2467, 2002.

[113] J. L. Wilkinson-Berka, G. Tan, K. Jaworski, and A. G. Miller, “Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology,” *Circulation Research*, vol. 104, no. 1, pp. 124–133, 2009.

[114] H. Y. Zeng, W. R. Green, and M. Q. M. Tso, “Microglial activation in human diabetic retinopathy,” *Archives of Ophthalmology*, vol. 126, no. 2, pp. 227–232, 2008.

[115] A. M. Joussen, V. Poulaki, N. Mitsiades et al., “Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression,” *The FASEB Journal*, vol. 16, no. 3, pp. 438–440, 2002.

[116] N. Demircan, B. G. Safran, M. Soylu, A. A. Ozcan, and S. Sizmaz, “Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy,” *Eye*, vol. 20, no. 12, pp. 1366–1369, 2006.

[117] H. Funatsu, H. Yamashita, H. Noma et al., “Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients,” *Graefes Archive for Clinical and Experimental Ophthalmology*, vol. 243, no. 1, pp. 3–8, 2005.
[118] R. A. Malik, C. Li, W. Aziz, J. A. Olson et al., “Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy,” Journal of Cellular and Molecular Medicine, vol. 9, no. 3, pp. 692–697, 2005.

[119] P. Murugeswari, D. Shukla, A. Rajendran, R. Kim, P. Namperumalsamy, and V. Muthukkaruppan, “Proinflammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with proliferative diabetic retinopathy and eales’ disease,” Retina, vol. 28, no. 6, pp. 817–824, 2008.

[120] K. I. Hiasa, M. Ishibashi, K. Ohtani et al., “Gene transfer of stromal cell-derived factor-1α enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization,” Circulation, vol. 109, no. 20, pp. 2454–2461, 2004.

[121] O. Arjamaa, M. Pöllönen, K. Kinnunen, T. Ryhänen, and K. Kaarniranta, “Increased IL-6 levels are not related to NFκB or HIF-1α transcription factors activity in the vitreous of proliferative diabetic retinopathy,” Journal of Diabetes and Its Complications, vol. 25, no. 6, pp. 393–397, 2011.

[122] G. H. Goodwin, C. Sanders, and E. W. Johns, “A new group of chromatin associated proteins with a high content of acidic and basic amino acids,” European Journal of Biochemistry, vol. 38, no. 1, pp. 14–19, 1973.

[123] M. T. Lotze and K. J. Tracey, “High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal,” Nature Reviews Immunology, vol. 5, no. 4, pp. 331–342, 2005.

[124] N. Arimura, Y. Ki-I, T. Hashiguchi et al., “Intraocular expression and release of high-mobility group box 1 protein in retinal detachment,” Laboratory Investigation, vol. 89, no. 3, pp. 278–289, 2009.

[125] T. Watanabe, H. Keino, Y. Sato, A. Kudo, H. Kawakami, and A. A. Okada, “High mobility group box protein-1 in experimental autoimmune uveoretinitis,” Investigative Ophthalmology and Visual Science, vol. 50, no. 5, pp. 2283–2290, 2009.

[126] O. Hori, J. Brett, T. Slattery et al., “The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. Mediation of neurite outgrowth and co-expression of RAGE and amphoterin in the developing nervous system,” The Journal of Biological Chemistry, vol. 270, no. 43, pp. 25752–25761, 1995.

[127] V. Jakšuš and N. Rietbrock, “Advanced glycation end-products and the progress of diabetic vascular complications,” Physiological Research, vol. 53, no. 2, pp. 131–142, 2004.

[128] S. Yang, K. Hirooka, Y. Liu et al., “Deleteurous role of anti-high mobility group box 1 monoclonal antibody in retinal ischemia-reperfusion injury,” Current Eye Research, vol. 36, no. 11, pp. 1037–1046, 2011.

[129] J. R. Klune, R. Dhupar, J. Cardinal, T. R. Billiar, and A. Tsung, “HMGB1: endogenous danger signaling,” Molecular Medicine, vol. 14, no. 7-8, pp. 476–484, 2008.

[130] H. S. Hreggvidsdottir, T. Östberg, H. Wåhåmaa et al., “The alarmin HMGB1 acts in synergy with endogenous and exogenous danger signals to promote inflammation,” Journal of Leukocyte Biology, vol. 86, no. 3, pp. 655–662, 2009.

[131] S. Mitola, M. Belleri, C. Urbinati et al., “Cutting edge: extracellular high mobility group box-1 protein is a proangiogenic cytokine,” Journal of Immunology, vol. 176, no. 1, pp. 12–15, 2006.

[132] F. Biscetti, G. Straface, R. de Cristofaro et al., “High-mobility group box-1 protein promotes angiogenesis after peripheral ischemia in diabetic mice through a VEGF-dependent mechanism,” Diabetes, vol. 59, no. 6, pp. 1496–1505, 2010.

[133] J. J. Lee, C. C. Hsiao, I. Yang et al., “High-mobility group box 1 protein is implicated in advanced glycation end products-induced vascular endothelial growth factor a production in the rat retinal ganglion cell line RGC-5,” Molecular Vision, vol. 18, pp. 838–850, 2012.

[134] P. M. Murphy, M. Baggiiolini, I. F. Charo et al., “International union of pharmacology. XXII. Nomenclature for chemokine receptors,” Pharmacological Reviews, vol. 52, no. 1, pp. 145–176, 2000.

[135] A. M. Abu El-Asrar, S. Struyf, D. Kangave, K. Geboes, and J. van Damme, “Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy,” European Cytokine Network, vol. 17, no. 3, pp. 155–165, 2006.

[136] K. H. Hong, J. Ryu, and K. H. Han, “Monocyte chemotactic protein-1-induced angiogenesis is mediated by vascular endothelial growth factor-A,” Blood, vol. 105, no. 4, pp. 1405–1407, 2005.

[137] M. D. Silverman, D. O. Zamora, Y. Pan et al., “Constitutive and inflammatory mediator-regulated fractalkine expression in human ocular tissues and cultured cells,” Investigative Ophthalmology and Visual Science, vol. 44, no. 4, pp. 1608–1615, 2003.

[138] J. J. You, C. H. Yang, J. S. Huang, M. S. Chen, and C. M. Yang, “Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis,” Investigative Ophthalmology and Visual Science, vol. 48, no. 11, pp. 5290–5298, 2007.

[139] Y. Wakabayashi, Y. Usui, Y. Okunuki et al., “Increased levels of monokine induced by interferon-γ (Mig) in the vitreous of patients with diabetic retinopathy,” Diabetic Medicine, vol. 25, no. 7, pp. 875–877, 2008.

[140] A. M. Joussen, V. Poulaki, M. L. Le et al., “A central role for inflammation in the pathogenesis of diabetic retinopathy,” The FASEB Journal, vol. 18, no. 12, pp. 1450–1452, 2004.

[141] J. I. Yamaguchi, K. E. Kusano, O. Masuo et al., “Stromal cell-derived factor-1 effects on ex vivo expanded endothelial progenitor cell recruitment for ischemic neovascularization,” Circulation, vol. 107, no. 9, pp. 1322–1328, 2003.

[142] E. de Falco, D. Porcelli, A. R. Torella et al., “SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells,” Blood, vol. 104, no. 12, pp. 3472–3482, 2004.

[143] D. H. Walter, J. Haendeler, J. Reinhold et al., “Impaired CXCR4 signaling contributes to the reduced neovascularization capacity of endothelial progenitor cells from patients with coronary artery disease,” Circulation Research, vol. 97, no. 11, pp. 1142–1151, 2005.

[144] K. Reddy, Z. Zhou, S. F. Jia et al., “Stromal cell-derived factor-1 stimulates vasogenesis and enhances Ewing’s sarcoma tumor growth in the absence of vascular endothelial growth factor,” International Journal of Cancer, vol. 123, no. 4, pp. 831–837, 2008.

[145] K. Stellos, H. Langer, K. Daub et al., “Platelet-derived stromal cell-derived factor-1 regulates adhesion and promotes differentiation of human CD34+ cells to endothelial progenitor cells,” Circulation, vol. 117, no. 2, pp. 206–215, 2008.

[146] J. M. Butler, S. M. Guthrie, M. Koc et al., “SDF-1 is both necessary and sufficient to promote proliferative retinopathy,” Journal of Clinical Investigation, vol. 115, no. 1, pp. 86–93, 2005.

[147] I. E. Blom, R. Goldschmeding, and A. Leask, “Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?” Matrix Biology, vol. 21, no. 6, pp. 473–482, 2002.
[148] A. M. Abu El-Asrar, S. Struyf, H. Verbeke, J. van Damme, and K. Geboes, “Circulating bone-marrow-derived endothelial precursor cells contribute to neovascularization in diabetic epiretinal membranes,” Acta Ophthalmologica, vol. 89, no. 3, pp. 222–228, 2011.

[149] M. A. C. Déry, M. D. Michaud, and D. E. Richard, “Hypoxia-inducible factor 1: regulation by hypoxic and non-hypoxic activators,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 3, pp. 535–540, 2005.

[150] N. M. Mazure, M. C. Brahi-mi-Horn, M. A. Berta et al., “HIF-1: master and commander of the hypoxic world: a pharmacological approach to its regulation by siRNAs,” Biochemical Pharmacology, vol. 68, no. 6, pp. 971–980, 2004.

[151] C. W. Pugh and P. J. Ratcliffe, “Regulation of angiogenesis by hypoxia: role of the HIF system,” Nature Medicine, vol. 9, no. 6, pp. 677–684, 2003.

[152] W. J. Lukü, A. Ottleczy, G. Lambrou et al., “Coordinate activation of HIF-1 and NF-κB DNA binding and COX-2 and VEGF expression in retinal cells by hypoxia,” Investigative Ophthalmology and Visual Science, vol. 44, no. 10, pp. 4163–4170, 2003.

[153] W. Gao, G. Ferguson, P. Connell et al., “High glucose concentrations alter hypoxia-induced control of vascular smooth muscle cell growth via a HIF-1α-dependent pathway,” Journal of Molecular and Cellular Cardiology, vol. 42, no. 3, pp. 609–619, 2007.

[154] C. Treins, S. Giorgetti-Peraldi, J. Murdaca, M. N. Monthouél-Kartmann, and E. van Obbergen, “Regulation of hypoxia-inducible factor (HIF)-1 activity and expression of HIF hydroxylases in response to insulin-like growth factor 1,” Molecular Endocrinology, vol. 19, no. 5, pp. 1304–1317, 2005.

[155] V. Poulaki, W. Qin, A. M. Joussen et al., “Acute intense insulin therapy exacerbates diabetic blood-retinal barrier breakdown via hypoxia-inducible factor-1α and VEGF,” Journal of Clinical Investigation, vol. 109, no. 6, pp. 805–815, 2002.

[156] A. M. A. El-Asrar, L. Missotten, and K. Geboes, “Expression of hypoxia-inducible factor-1α and the protein products of its target genes in diabetic fibrovascular epiretinal membranes,” British Journal of Ophthalmology, vol. 91, no. 6, pp. 822–826, 2007.

[157] J. L. Lim, C. Spee, and D. R. Hinton, “A comparison of hypoxia-inducible factor-α in surgically excised neovascular membranes of patients with diabetes compared with idiopathic epiretinal membranes in nondiabetic patients,” Retina, vol. 30, no. 9, pp. 1472–1478, 2010.

[158] S. Frede, C. Stockmann, P. Freitag, and J. Fandrey, “Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44/42 MAPK and NF-κB,” Biochemical Journal, vol. 396, no. 3, pp. 517–527, 2006.

[159] S. Bonello, C. Zähringer, R. S. BelAiba et al., “Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 4, pp. 755–761, 2007.

[160] K. Kinnunen, T. Puustjärvi, M. Teräsvirta et al., “Differences in retinal neovascular tissue and vitreous humour in patients with type 1 and type 2 diabetes,” British Journal of Ophthalmology, vol. 93, no. 8, pp. 1109–1115, 2009.

[161] O. Arjamaa, M. Nikinmaa, A. Salminen, and K. Kaarniranta, “Regulatory role of HIF-1α in the pathogenesis of age-related macular degeneration (AMD),” Ageing Research Reviews, vol. 8, no. 4, pp. 349–358, 2009.

[162] A. Salminen and K. Kaarniranta, “Insulin/IGF-1 paradox of aging: regulation via AKT/IKK/NF-κB signaling,” Cellular Signalling, vol. 22, no. 4, pp. 573–577, 2010.

[163] N. Ferrara, H. P. Gerber, and J. LeCouter, “The biology of VEGF and its receptors,” Nature Medicine, vol. 9, no. 6, pp. 669–676, 2003.

[164] H. Takahashi and M. Shibuya, “The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions,” Clinical Science, vol. 109, no. 3, pp. 227–241, 2005.

[165] M. Shibuya, N. Ito, and L. Claesson-Welsh, “Structure and function of vascular endothelial growth factor receptor-1 and -2,” Current Topics in Microbiology and Immunology, vol. 237, pp. 60–83, 1999.

[166] P. A. Campochiaro, “Ocular neovascularisation and excessive vascular permeability,” Expert Opinion on Biological Therapy, vol. 4, no. 9, pp. 1395–1402, 2004.

[167] S. Hiratsuka, Y. Katoaka, K. Nakao et al., “Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos,” Molecular and Cellular Biology, vol. 25, no. 1, pp. 355–363, 2005.

[168] Y. Sakurai, K. Ohgimoto, Y. Katoaka, N. Yoshida, and M. Shibuya, “Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 4, pp. 1076–1081, 2005.

[169] T. Asahara, C. Bauters, C. Pastore et al., “Local delivery of vascular endothelial growth factor accelerates reendothelialization and attenuates intimal hyperplasia in balloon-injured rat carotid artery,” Circulation, vol. 91, no. 11, pp. 2793–2801, 1995.

[170] G. Gennaro, C. Ménard, S. E. Michaud, and A. Rivard, “Age-dependent impairment of reendothelialization after arterial injury: role of vascular endothelial growth factor,” Circulation, vol. 107, no. 2, pp. 230–233, 2003.

[171] M. Safran and W. G. Kaelin Jr., “HIF hydroxylation and the mammalian oxygen-sensing pathway,” Journal of Clinical Investigation, vol. 111, no. 6, pp. 779–783, 2003.

[172] E. Ikeda, M. G. Achen, G. Breier, and W. Risau, “Hypoxia-induced transcriptional activation and increased mRNA stability of vascular endothelial growth factor in C6 glioma cells,” The Journal of Biological Chemistry, vol. 270, no. 34, pp. 19761–19766, 1995.

[173] A. P. Levy, N. S. Levy, S. Wegner, and M. A. Goldberg, “Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia,” The Journal of Biological Chemistry, vol. 270, no. 22, pp. 13333–13340, 1995.

[174] I. Stein, M. Neeman, D. Shewei, A. Itin, and E. Keshet, “Stabilization of vascular endothelial growth factor mRNA by hypoxia and hypoglycemia and coregulation with other ischemia-induced genes,” Molecular and Cellular Biology, vol. 15, no. 10, pp. 5363–5368, 1995.

[175] R. J. Melder, G. C. Koenig, B. P. Witwer, N. Safabakhsh, L. L. Munn, and R. K. Jain, “During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium,” Nature Medicine, vol. 2, no. 9, pp. 992–997, 1996.

[176] P. C. S. Lu, H. Ye, M. Maeda, and D. T. Azar, “Immunolocalization and gene expression of matrilysin during corneal wound healing,” Investigative Ophthalmology and Visual Science, vol. 40, no. 1, pp. 20–27, 1999.

[177] J. K. Min, Y. M. Kim, S. W. Kim et al., “TNF-related activation-induced cytokine enhances leukocyte adhesiveness: induction
of ICAM-1 and VCAM-1 via TNF receptor-associated factor and protein kinase C-dependent NF-κB activation in endothelial cells,” *Journal of Immunology*, vol. 175, no. 1, pp. 531–540, 2005.

[178] A. C. Clermont, L. P. Aiello, F. Morì, L. M. Aiello, and S. E. Bursell, “Vascular endothelial growth factor and severity of nonproliferative diabetic retinopathy mediate retinal hemodynamics in vivo: a potential role for vascular endothelial growth factor in the progression of nonproliferative diabetic retinopathy,” *American Journal of Ophthalmology*, vol. 124, no. 4, pp. 433–446, 1997.

[179] A. P. Adams, J. W. Miller, M. T. Bernal et al., “Increased vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy,” *American Journal of Ophthalmology*, vol. 118, no. 4, pp. 445–450, 1994.

[180] N. Matsunaga, Y. Chikaraishi, H. Izuta et al., “Role of soluble vascular endothelial growth factor receptor-1 in the vitreous in proliferative diabetic retinopathy,” *Ophthalmology*, vol. 115, no. 11, pp. 1916–1922, 2008.

[181] H. Ozaki, M. S. Seo, K. Ozaki et al., “Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization,” *American Journal of Pathology*, vol. 156, no. 2, pp. 697–707, 2000.

[182] C. Kaur, V. Sivakumar, and W. S. Foulds, “Early response of neurons and glial cells to hypoxia in the retina,” *Investigative Ophthalmology and Visual Science*, vol. 47, no. 3, pp. 1125–1141, 2006.

[183] C. Kaur, V. Sivakumar, Z. Yong, J. Lu, W. S. Foulds, and E. A. Ling, “Blood-retinal barrier disruption and ultrastructural changes in the hypoxic retina in adult rats: the beneficial effect of melatonin administration,” *Journal of Pathology*, vol. 212, no. 4, pp. 429–439, 2007.

[184] J. S. Penn, A. Madan, R. B. Caldwell, M. Bartoli, R. W. Caldwell, and M. E. Hartnett, “Vascular endothelial growth factor in eye disease,” *Progress in Retinal and Eye Research*, vol. 27, no. 4, pp. 331–371, 2008.

[185] S. Kondo, S. Kubota, T. Shimo et al., “Connective tissue growth factor increased by hypoxia may initiate angiogenesis in collaboration with matrix metalloproteinases,” *Carcinogenesis*, vol. 23, no. 5, pp. 769–776, 2002.

[186] L. Pi, H. Xia, J. Liu, A. K. Shenoy, W. W. Hauswirth, and E. W. Scott, “Role of connective tissue growth factor in the retinal vasculature during development and ischemia,” *Investigative Ophthalmology and Visual Science*, vol. 52, no. 12, pp. 8701–8710, 2011.

[187] E. E. Moussad and D. R. Brigstock, “Connective tissue growth factor. What’s in a name?” *Molecular Genetics and Metabolism*, vol. 71, no. 1-2, pp. 276–292, 2000.

[188] T. Kita, Y. Hata, M. Miura, S. Kawahara, S. Nakao, and T. Ishibashi, “Functional characteristics of connective tissue growth factor on vitreoretinal cells,” *Diabetes*, vol. 56, no. 5, pp. 1421–1428, 2007.

[189] E. J. Kuiper, F. A. van Nieuwenhoven, M. D. de Smet et al., “The angio-fibrotic switch of VEGF and CTGF in proliferative diabetic retinopathy,” *PLoS ONE*, vol. 3, no. 7, Article ID e2675, 2008.

[190] S. S. Fazel, L. Chen, D. Angoulvant et al., “Activation of c-kit is necessary for mobilization of reparative bone marrow progenitor cells in response to cardiac injury,” *The FASEB Journal*, vol. 22, no. 3, pp. 930–940, 2008.

[191] P. H. Huang, Y. H. Chen, C. H. Wang et al., “Matrix metalloproteinase-9 is essential for ischemia-induced neovascularization by modulating bone marrow-derived endothelial progenitor cells,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 8, pp. 1179–1184, 2009.

[192] T. S. Li, K. Hamano, M. Nishida et al., “CD117+ stem cells play a key role in therapeutic angiogenesis induced by bone marrow cell implantation,” *American Journal of Physiology*, vol. 285, no. 3, pp. H931–H937, 2003.

[193] Y. Miyamoto, T. Suyama, T. Yashita, H. Akimaru, and H. Kurata, “Bone marrow subpopulations contain distinct types of endothelial progenitor cells and angiogenic cytokine-producing cells,” *Journal of Molecular and Cellular Cardiology*, vol. 43, no. 5, pp. 627–635, 2007.

[194] P. Dentelli, A. Rosso, A. Balsamo et al., “C-KIT, by interacting with the membrane-bound ligand, recruits endothelial progenitor cells to inflamed endothelium,” *Blood*, vol. 109, no. 10, pp. 4264–4271, 2007.

[195] J. Matsui, T. Wakabayashi, M. Asada, K. Yoshimatsu, and M. Okada, “Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells,” *The Journal of Biological Chemistry*, vol. 279, no. 18, pp. 18600–18607, 2004.

[196] J. P. D. van Huyen, D. M. Smadja, P. Bruneval et al., “Bone marrow-derived mononuclear cell therapy induces distal angiogenesis after local injection in critical leg ischemia,” *Modern Pathology*, vol. 21, no. 7, pp. 837–846, 2008.

[197] D. J. Kelly, Y. Zhang, R. M. Gow, S. Iseccu, and R. E. Gilbert, “Cells expressing the stem cell factor receptor, c-kit, contribute to neoangiogenesis in diabetes,” *Diabetes and Vascular Disease Research*, vol. 2, no. 2, pp. 76–80, 2005.

[198] M. Bosch-Marce, H. Okuyama, J. B. Wesley et al., “Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after limb ischemia,” *Circulation Research*, vol. 101, no. 12, pp. 1310–1318, 2007.

[199] A. M. Abu. El-Asrar, S. Struyf, G. Opdenakker, J. van Damme, and K. Geboes, “Expression of stem cell factor/c-kit signaling pathway components in diabetic fibrovascular epiretinal membranes,” *Molecular Vision*, vol. 16, pp. 1098–1107, 2010.

[200] V. Poulaki, A. M. Joussen, N. Mitsiades, C. S. Mitsiades, E. F. Iliaki, and A. P. Adamis, “Insulin-like growth factor-I plays a pathogenetic role in diabetic retinopathy,” *American Journal of Pathology*, vol. 165, no. 2, pp. 457–469, 2004.

[201] S. Uthra, R. Raman, B. N. Mukesh et al., “Diabetic retinopathy and IGF-1 gene polymorphic cytokine-adenine repeats in a Southern Indian cohort,” *Ophthalmic Research*, vol. 39, no. 5, pp. 294–299, 2007.

[202] A. Bikfalvi and Z. C. Han, “Angiogenic factors are hematopoietic growth factors and vice versa,” *Leukemia*, vol. 8, no. 3, pp. 523–529, 1994.

[203] S. B. Krantz, “Erythropoietin,” *Blood*, vol. 77, no. 3, pp. 419–434, 1991.

[204] D. Watanabe, K. Suzuma, S. Matsui et al., “Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy,” *The New England Journal of Medicine*, vol. 353, no. 8, pp. 782–792, 2005.

[205] H. Takagi, D. Watanabe, K. Suzuma et al., “Novel role of erythropoietin in proliferative diabetic retinopathy,” *Diabetes Research and Clinical Practice*, vol. 77, no. 3, supplement, pp. S62–S64, 2007.
[206] S. P. Becerra and J. Amaral, “Erythropoietin—an endogenous retinal survival factor,” The New England Journal of Medicine, vol. 347, no. 24, pp. 1968–1970, 2002.

[207] J. L. Wilkinson-Berca and E. L. Fletcher, “Angiotensin and bradykinin: targets for the treatment of vascular and neuroglial pathology in diabetic retinopathy,” Current Pharmaceutical Design, vol. 10, no. 27, pp. 3313–3330, 2004.

[208] J. H. Kim, J. H. Kim, Y. S. Yu, C. S. Cho, and K. W. Kim, “Blockade of angiotensin II attenuates VEGF-mediated blood-retinal barrier breakdown in diabetic retinopathy,” Journal of Cerebral Blood Flow and Metabolism, vol. 29, no. 3, pp. 621–628, 2009.

[209] S. I. Yamagishi, K. Nakamura, and T. Imaizumi, “Advanced glycation end products (AGEs) and diabetic vascular complications,” Current Diabetes Reviews, vol. 1, no. 1, pp. 93–106, 2005.

[210] J. M. Hughes, E. J. Kuiper, I. Klaassen et al., “Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina,” Diabetologia, vol. 50, no. 5, pp. 1089–1098, 2007.

[211] S. I. Yamagishi, T. Matsu, K. Nakamura et al., “Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression,” Microvascular Research, vol. 75, no. 1, pp. 130–134, 2008.

[212] K. Chmielewska, J. Robaszkiewicz, and M. Kosatka, “Role of the retinal pigment epithelium (RPE) in the pathogenesis and treatment of diabetic macular edema (DME),” Klinika Oczna, vol. 110, no. 7–9, pp. 318–320, 2008.

[213] K. Horiuchi, N. Amizuka, S. Takeshita et al., “Identiﬁcation and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor β,” Journal of Bone and Mineral Research, vol. 14, no. 7, pp. 1239–1249, 1999.

[214] S. Yoshida, K. Ishikawa, R. Asato et al., “Increased expression of periostin in vitreous and ﬁbrovascular membranes obtained from patients with proliferative diabetic retinopathy,” Investigative Ophthalmology and Visual Science, vol. 52, no. 8, pp. 5670–5678, 2011.

[215] K. Ishikawa, S. Yoshida, K. Kadota et al., “Gene expression profile of hyperoxic and hypoxic retinas in a mouse model of oxygen-induced retinopathy,” Investigative Ophthalmology and Visual Science, vol. 51, no. 8, pp. 4307–4319, 2010.

[216] S. Yoshida, A. Yoshida, T. Ishibashi, S. G. Elner, and V. M. Elner, “Role of MCP-1 and MIP-1α in retinal neovascularization during postischemic inﬂammation in a mouse model of retinal neovascularization,” Journal of Leukocyte Biology, vol. 73, no. 1, pp. 137–144, 2003.

[217] K. Tateto, M. Hosoya, Y. Habata et al., “Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor,” Biochemical and Biophysical Research Communications, vol. 251, no. 2, pp. 471–476, 1998.

[218] B. Masri, B. Knibiehler, and Y. Audigier, “Apelin signalling: a promising pathway from cloning to pharmacology,” Cellular Signalling, vol. 17, no. 4, pp. 415–426, 2005.

[219] E. Devic, K. Rizzoti, S. Bodin, B. Knibiehler, and Y. Audigier, “Amino acid sequence and embryonic expression of msr/apj, the mouse homolog of Xenopus X-msr and human API,” Mechanisms of Development, vol. 84, no. 1-2, pp. 199–203, 1999.

[220] M. J. Kleinz and A. P. Davenport, “Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells,” Regulatory Peptides, vol. 118, no. 3, pp. 119–125, 2004.

[221] C. M. Cox, S. L. D’Agostino, M. K. Miller, R. L. Heimarck, and P. A. Krieg, “Apelin, the ligand for the endothelial G-protein-coupled receptor, APJ, is a potent angiogenic factor required for normal vascular development of the frog embryo,” Developmental Biology, vol. 296, no. 1, pp. 177–189, 2006.

[222] J. Qian, Q. Lu, Y. Tao, and Y. R. Jiang, “Vitreous and plasma concentrations of apelin and vascular endothelial growth factor after intravitreal bevacizumab in eyes with proliferative diabetic retinopathy,” Retina, vol. 31, no. 1, pp. 161–168, 2011.

[223] N. Ferrara, R. D. Mass, C. Campa, and R. Kim, “Targeting VEGF-A to treat cancer and age-related macular degeneration,” Annual Review of Medicine, vol. 58, pp. 491–504, 2007.

[224] J. Frystyk, L. Tarnow, T. Krarup Hansen, H. H. Parving, and A. Flyvbjerg, “Increased serum adiponectin levels in type 1 diabetic patients with microvascular complications,” Diabetologia, vol. 48, no. 9, pp. 1911–1918, 2005.

[225] N. Mohan, F. Monickaraj, M. Balasubramanyam, M. Rema, and V. Mohan, “Imbalanced levels of angiogenic and angiotropic factors in vitreous, plasma and postmortem retinal tissue of patients with proliferative diabetic retinopathy,” Journal of Diabetes and Its Complications, vol. 26, no. 5, pp. 435–441, 2012.

[226] D. Mao, H. Peng, Q. Li et al., “Aqueous humor and plasma adiponectin levels in proliferative diabetic retinopathy patients,” Current Eye Research, vol. 37, no. 9, pp. 803–808, 2012.